Glutathione Injection - Uses

What is Glutathione?

Medical / Clinical Uses

1. Liver Support and Hepatoprotection

• Glutathione depletion in the liver is a key step in hepatotoxic injury - most notably in paracetamol (acetaminophen) overdose, where the toxic metabolite NAPQI causes necrosis once GSH falls below a critical threshold (Sleisenger and Fordtran's GI and Liver Disease).
• IV glutathione (1800 mg/day) has been studied for chronic fatty liver disease (NAFLD/NASH) and alcoholic liver disease, where it improved markers like bilirubin levels.
• Supports liver detoxification by participating in Phase II conjugation reactions (glutathione S-transferase pathway).

2. Parkinson's Disease

• IV glutathione has been evaluated for symptomatic relief in Parkinson's disease, with some early studies reporting reduction in tremors and motor symptoms. The rationale is that dopaminergic neurons in the substantia nigra are especially vulnerable to oxidative stress and show markedly depleted GSH levels.
• Evidence remains preliminary - N-acetylcysteine (NAC), a GSH precursor, is more commonly studied in this context (recent systematic review, PMID 40988585).

3. Chemotherapy/Oncology Support

• Used as an adjunct during platinum-based chemotherapy (cisplatin) to reduce peripheral neuropathy and nephrotoxicity without significantly diminishing antitumor efficacy.
• Also studied for reducing chemotherapy-induced oxidative damage.

4. Skin Lightening / Hyperpigmentation (Cosmetic)

• This is the most widely marketed use, especially in Asia. Glutathione inhibits tyrosinase, shifting melanin synthesis from eumelanin (dark) to phaeomelanin (lighter pigment).
• A 2025 systematic review (PMID 39444151) in the International Journal of Dermatology found limited, low-quality evidence for IV glutathione in skin lightening and melasma - results are temporary, and the International Journal of Dermatology states IV glutathione is contraindicated for cosmetic use due to lack of efficacy evidence and documented adverse events.
• A 2025 narrative review (PMID 40013212) similarly concluded evidence for skin lightening is weak and safety data are insufficient.

5. HIV/AIDS

• Glutathione is severely depleted in HIV-positive patients. IV supplementation has been studied to improve immune function and reduce oxidative damage, though oral NAC is more commonly used in practice.

6. Cystic Fibrosis

• Inhaled and IV glutathione have been explored to reduce oxidative lung damage in cystic fibrosis (though inhaled forms can exacerbate asthma in susceptible individuals).

7. Peripheral Arterial Disease

• Some evidence suggests IV glutathione improves walking distance in patients with peripheral arterial occlusive disease by reducing oxidative endothelial damage.

8. Diabetes and Insulin Resistance

• Studied for reducing tissue damage in diabetics and improving insulin sensitivity, with some evidence for improved fat metabolism in older patients.

9. COVID-19 / Respiratory Illness

• During the pandemic, IV glutathione was studied as an adjunct antioxidant therapy to reduce cytokine storm and oxidative lung injury, with thiol-based compounds (including GSH) showing some mechanistic rationale (PMID 34448938).

10. Autism Spectrum Disorder

• Investigated for behavioral and metabolic improvements in children with ASD, given documented redox imbalances in this population. A recent RCT (PMID 39960783) studied glutathione with vitamin C and cysteine, showing some benefit in disruptive behavior.

Mechanism of Action

Administration

• Intravenous (IV): Most common for medical indications; fastest bioavailability
• Intramuscular (IM): Used for cosmetic/skin lightening protocols
• Dose range: Varies widely by indication - typically 600 mg to 2400 mg per session
• Must be administered by a healthcare professional under medical supervision

Important Safety Notes

• Not FDA-approved for any specific indication as an injectable - most compounded formulations are used off-label
• Reported adverse effects: flushing, weight gain, loose stools, flatulence; a case report documents reversible severe hepatic injury from IV use
• Contraindicated in: pregnancy/lactation (insufficient safety data), active liver or kidney disease (paradoxically), sulfur compound allergy, some autoimmune conditions
• A July 2025 review (PMID 40408806) cautions against misuse of IV glutathione combined with ozone as an antioxidant therapy
• Long-term safety data are lacking; medical oversight is strongly recommended

Is Dairy a Reason for Acne?

What the Evidence Says

Textbook Position

"Dairy ingestion appears to be weakly associated with acne... Both [high glycemic diets and dairy] are thought to increase insulin-like growth factor (IGF)-1 with possible increase in androgen activity and sebocyte modulation, therefore promoting acne."

Systematic Review Evidence

The Biological Mechanism - How Does Dairy Cause Acne?

1. IGF-1 Stimulation

• Sebaceous gland oil (sebum) production
• Androgen synthesis (testosterone-like hormones)
• Keratinocyte proliferation - causing follicular plugging

2. mTORC1 / FoxO1 Signaling

3. Hormones in Milk

4. Whey Protein (Not Just Milk)

Skim vs. Whole Milk - An Interesting Finding

• Fat removal concentrates the whey protein and hormones per volume
• Whole milk may have competing factors (fat content, different protein ratios) that partially blunt the response

What Type of Dairy Matters

Important Caveats

• The effect is individual - not everyone who consumes dairy gets worse acne
• Most studies are observational (questionnaire-based), not controlled trials - confounding is possible
• Dairy is one factor in a multifactorial disease that also involves genetics, hormones, sebum composition, C. acnes bacteria, and skin immune responses
• Eliminating dairy alone does not guarantee acne clearance, but is a reasonable dietary modification to trial alongside treatment

Practical Takeaway

Cequa 0.09% - Minimum Duration of Use

Key Facts from the Official Prescribing Information

• Both pivotal Phase 2/3 and Phase 3 clinical trials (NCT #02254265 and NCT #02688556) ran for 84 days (12 weeks)
• The primary efficacy endpoint - a statistically significant increase in tear production (Schirmer test ≥10 mm from baseline) - was measured at Day 84
• Results: ~17% of Cequa-treated patients showed meaningful tear production improvement vs ~9% of vehicle at Day 84

Onset of Effect Timeline

Important Points

• The FDA prescribing information does not state a specific minimum number of days as a hard rule, but the entire evidence base for the drug is built on a 12-week (84-day) treatment period
• Clinical guidelines and prescribing practice treat 3 months (84 days) as the minimum before deciding whether the drug is working
• Cequa is a long-term, ongoing treatment - it does not have a fixed course like antibiotics. If effective, it is continued indefinitely
• The drug does not provide immediate symptom relief - it works by gradually reducing ocular surface inflammation to restore natural tear production

Bottom Line

Cequa 0.09% - Side Effects

Most Common (>5% of patients - from clinical trials)

Common (1% - 5% of patients)

• Blepharitis (eyelid inflammation/swelling at the lid margin)
• Eye irritation
• Headache
• Urinary tract infection

Other Reported Side Effects (from Canadian product monograph and post-market data)

• Eye pain
• Eye redness / irritation around the eye
• Feeling of something in the eye (foreign body sensation)
• Blurred vision
• Watering / tearing (epiphora)
• Eye discharge
• Increased sensitivity to light (photophobia)
• Eye strain (asthenopia)
• Itching or discomfort around the eye
• Increased intraocular pressure
• Conjunctivitis (pink eye)

• Throat irritation
• Sore throat / cough
• Headache
• Nausea
• Dizziness
• Ear pain

Post-Marketing (rare, reported voluntarily)

• Ear and labyrinth disorders (ear pain)
• Additional eye disorders identified after approval

Important Safety Notes

• Most adverse events were mild to moderate - the drug was generally well tolerated in trials
• Only 3.2% of patients discontinued due to ocular adverse events
• Contact lenses must be removed before instillation and can be reinserted after 15 minutes
• Do not touch the vial tip to the eye or any surface (contamination risk)
• The nanomicellar formulation of Cequa was specifically designed to reduce local side effects compared to older cyclosporine formulations (Restasis 0.05%)
• A recent Phase 4 study (PMC12968827) found instillation-site pain occurred at a much lower rate (2.2%) in real-world use than in the original pivotal trials (22%), suggesting patients acclimate over time